首页预防卫生流行病学流行病学 07 第七章 筛检.pptx

07 第七章 筛检.pptx

页数:65页文件大小:783.8 KB来源: 流行病学ppt课件

本课件讲解筛检的概念与实施条件,围绕筛检试验的评价指标展开,说明灵敏度、特异度、假阳性率与假阴性率的计算,并讲解预测值、ROC曲线与联合试验的评价方法,以及筛查项目中的偏倚。

筛检封面,概述本章的主题构成与内容框架
Stage,StageofsusceptibilityStageofSu
目录,依次说明目录、概述、筛检试验的评价等内容
查看本课件的文字版(共 65 页,供检索与复制)

第1页:筛检

筛检Screening

第2页:Stage

Stage ofsusceptibilityStage ofSubclinicalDiseaseStage ofClinical DiseaseStage of Recovery,Disability, or DeathExposurePathologicalChangesOnset ofSymptomsUsual Timeof Diagnosis疾病自然史(Natural History of Disease)

第3页:目录

目录

  • 概述
  • 筛检试验的评价
  • 筛检效果的评价
  • Introduction
  • Evaluation of screening test
  • Evaluation of effectivenessOutline

第4页:筛检是运用快速,简便的试验

筛检是运用快速、简便的试验、检查或其他方法,将健康人群中那些可能有病或缺陷,但表面健康的人、同那些可能无病者鉴别开来Screeningis defined as theuse of quick and simple testingprocedures to identify andseparate persons who areapparently well, but who maybe at risk of a disease, fromthose who probably do nothave the disease.第一节概述Introduction

第5页:Apparently Well

Apparently Well Population to be TestedScreeningTestDiagnostic TestDisease or RiskFactor PresentDisease or RiskFactor AbsentNegatives(Normal) (Persons presumedto be free of disease)Negative on screeningPositive on screen, no diseasePositive on screen, disease presentPositives(abnormal)presumed tohave diseaseTreatmentIntervention筛检试验流程图Flow diagram of screening test

第6页:筛查方法的评价与选择程序

筛查方法的评价与选择程序Procedures of evaluation and selection for screening test金标准(gold standard)目标人群Targetpopulation病人Patient非病人Non-patient待评价筛查方法Screening to beevaluated评价指标Evaluation indicator+-+-

第7页:筛检试验

筛检试验Screening test识别健康人群中未被发现的某病患者或可疑患者,或高危个体Screening is the detection of patients,suspected patient and high risk of thedisease in healthy population

第8页:筛检试验, ,问卷,常规体格检查

筛检试验Screening test问卷、常规体格检查、物理学检查、实验室检验、分子生物学技术Questionnaire, routine physicalexamination, physical examination,laboratory tests, molecular biologytechniques

第9页:根据所用的筛检方法的数量多少

根据所用的筛检方法的数量多少

  • 单项筛检
  • 多项筛选筛检的分类Categories of screeningBased on the on the quantityof screening methodsSingle screeningMultiple screening

第10页:根据筛检对象的范围不同

根据筛检对象的范围不同

  • 人群筛检
  • 目标筛检筛检的分类Categories of screeningBased on the scope ofscreening subjectsMass screeningTargeted screening

第11页:简单性廉价性快速性安全性可接受性筛检试验

简单性廉价性快速性安全性可接受性筛检试验应具备五个特征Five characteristics that screening testshould haveSimpleCheapQuickSafeAcceptable

第12页:一级预防二级预防疾病的自然史流行病学检测

一级预防二级预防疾病的自然史流行病学检测筛检的目的Primary preventionSecondary preventionNatural history of diseaseEpidemiologicalsurveillancePurposes of screening

第13页:筛检的疾病是当地一个重大的公共卫生问题

筛检的疾病是当地一个重大的公共卫生问题

  • 具备有效的治疗或预防方法应用筛检的原则Principles for the application of screeningThe disease being screenedshould be a major problemAcceptable treatment orprevention methods should beavailable for individuals withdiseases discovered in thescreening process.

第14页:有进一步确诊的方法与条件

有进一步确诊的方法与条件

  • 该病的自然史明确A suitable and effective testor examination for thedisease should be availableThe natural history of thedisease should beadequately understood应用筛检的原则Principles for the application of screening

第15页:该病具有较长的潜伏期或领先时间

该病具有较长的潜伏期或领先时间

  • 预期有良好的筛检效益The disease should have arecognizable course, withearly and latent states ofthe disease beingidentifiableExpected good efficiency ofscreening should beavailable应用筛检的原则Principles for the application of screening

第16页:伦理学问题, ,尊重个人意愿,’

伦理学问题Ethical Issues尊重个人意愿Respectforperson’swill有益无害Usefulandharmless公正Fairness

第17页:一、筛检试验的评价方法

一、筛检试验的评价方法

  • 确定金标准(Determine Gold Standard)
  • 选择研究对象(Chose Study Subjects)
  • 样本量的估计(Estimate Sample Size)
  • 整理评价结果(Sort out evaluation result)第二节筛检试验的评价Evaluation of Screening test

第18页:金标准所谓“金标准”是指当前临床医学界公

金标准所谓“金标准”是指当前临床医学界公认的诊断疾病的最可靠方法GoldStandardThe best available test thatis universally recognized byclinical medical circles iscalled the GOLDSTANDARD.

第19页:病例组纳入各种类型的病人对照组最好选择需

病例组纳入各种类型的病人对照组最好选择需要与研究疾病鉴别的其他病人,即所选择的对照组与病例组具有许多相似的条件研究对象Study SubjectsCase groupInclude appropriatespectrum of patientsControl groupNeed to be distinguished tothe disease studied, that is thecontrol has co-morbidconditions with case

第20页:样本量、 、影响样本量的因素

  • 样本量Sample Size影响样本量的因素
  • 待评价筛检试验的灵敏度
  • 待评价筛检试验的特异度
  • 显著性水平(α)
  • 允许误差(d)Factors determine sample sizeSensitivity of screening to beevaluatedSpecificity of screening to beevaluatedSignificance level(α)Allowable error(d)

第21页:当待评价筛检试验的灵敏度和特异度均接近

当待评价筛检试验的灵敏度和特异度均接近50%Both sensitivity and specificity of screeningto be evaluated approach 50%n: the number of abnormal (diseased) or normal (healthy) patientsin the study.δ: admissible error.P: the estimation of sensitivity and specificity for testing.ua: the u value for the cumulative probability equal to a/2.

第22页:当待评价筛检试验的灵敏度和特异度小于

当待评价筛检试验的灵敏度和特异度小于20%或大于80%Both sensitivity and specificity of screening to be evaluatedless than 20% or greater than 80%

第23页:本来有病,被筛检为阳性本来有病

本来有病,被筛检为阳性本来有病,被筛检为阴性本来无病,被筛检为阳性本来无病,被筛检为阴性评价结果Evaluation Results

第24页:评价结果、 、 、-+

评价结果Evaluation ResultsDisease Status(Gold Standard)-+TestPositiveFree of disease,test positiveb(FP)Have disease,test positivea(TP)+TestResultTestNegativeFree of disease,test negatived(TN)Have disease,test negativec(FN)-Freeof diseaseHavedisease

第25页:真实性(、)

  • 真实性(validity)
  • 可靠性(reliability)
  • 预测值(predictive value)二、筛检试验的评价指标Evaluation Index

第26页:灵敏度(、)

  • 灵敏度(sensitivity)
  • 假阴性率(false negative rate)合计(total)金标准(gold standard)筛检试验(screening)非患者(non-patient)患者(patient)R1假阳性(FP)B真阳性(TP)A阳性(positive)R2真阴性(TN)D假阴性(FN)C阴性(negative)NC2C1合计(total)真实性(validity)

第27页:False Negative

False Negative RateLikelihood of a negative result when patient actuallyhas diseaseFalseNegativesSensitivity

第28页:False Negatives

FalseNegativesSensitivityLikelihood of a negative result when patient actuallyhas diseaseFalse Negative Rate

第29页:False negative

False negative rate increases with decreased sensitivitySensitivityFalseNegativesFalse Negative RateLikelihood of a negative result when patient actuallyhas disease

第30页:特异度(、)

  • 特异度(specificity)
  • 假阳性率(false positive rate)合计(total)金标准(gold standard)筛检试验(screening)非患者(non-patient)患者(patient)R1假阳性(FP)B真阳性(TP)A阳性(positive)R2真阴性(TN)D假阴性(FN)C阴性(negative)NC2C1合计(total)真实性(validity)

第31页:False Positive

False Positive RateLikelihood of a positive result when patient doesnot have the diseaseFalsePositivesSpecificity

第32页:False Positive

False Positive RateLikelihood of a positive result when patient doesnot have the diseaseFalsePositivesSpecificity

第33页:False Positive

False Positive RateLikelihood of a positive result when patient doesnot have the diseaseFalse positive rate increases with decreased specificitySpecificityFalsePositives

第34页:正确指数(,’s

正确指数(Youden’s index)=(特异度+灵敏度)-1=1-(假阳性率+假阴性率)真实性(validity)合计(total)金标准(gold standard)筛检试验(screening)非患者(non-patient)患者(patient)R1假阳性(FP)B真阳性(TP)A阳性(positive)R2真阴性(TN)D假阴性(FN)C阴性(negative)NC2C1合计(total)

第35页:阳性似然比(、 、 、,+、)

  • 阳性似然比(positive likelihood ratio,+LR)
  • 阴性似然比(negative likelihood ratio,-LR)真实性(validity)合计(total)金标准(gold standard)筛检试验(screening)非患者(non-patient)患者(patient)R1假阳性(FP)B真阳性(TP)A阳性(positive)R2真阴性(TN)D假阴性(FN)C阴性(negative)NC2C1合计(total)

第36页:真实性(,)合计金标准筛检试验非患者

  • 真实性(validity)合计(total)金标准(gold standard)筛检试验(screening)非患者(non-patient)患者(patient)R1假阳性(FP)B真阳性(TP)A阳性(positive)R2真阴性(TN)D假阴性(FN)C阴性(negative)NC2C1合计(total)
  • 一致率(agreement rate),符合率一致率

第37页:真实性(,)合计金标准筛检试验非患者

真实性(validity)合计(total)金标准(gold standard)筛检试验(screening)非患者(non-patient)患者(patient)R1假阳性(FP)B真阳性(TP)A阳性(positive)R2真阴性(TN)D假阴性(FN)C阴性(negative)NC2C1合计(total)取值范围:-1和+1之间Range: between-1 and +1Kappa值判断标准Kappa值一致性强度<0弱0~0.2轻0.21~0.40尚好0.41~0.60中度0.61~0.80高度0.81~1最强

第38页:Kappa值

Kappa值

  • 观察一致性(Observation consistency)
  • 机遇一致性(Opportunity consistency)
  • 非机遇一致性(Non-opportunity consistency)
  • 实际一致性(Actral consistency)真实性(validity)合计(total)金标准(gold standard)筛检试验(screening)非患者(non-patient)患者(patient)R1假阳性(FP)B真阳性(TP)A阳性(positive)R2真阴性(TN)D假阴性(FN)C阴性(negative)NC2C1合计(total)

第39页:标准差与变异系数

标准差与变异系数

  • 符合率(agreement rate)Agreement rateTotalScreening test 1Screening test 2NegativePositiveR1BAPositiveR2DCNegativeNC2C1Total可靠性(reliability)

第40页:影响可靠性的因素

影响可靠性的因素

  • 受试对象生物学变异
  • 观察变异
  • 实验室条件

第41页:阳性预测值

阳性预测值

  • 阴性预测值(negative predictive value)TotalGold standardScreening testNon-patientPatientR1False Positive BTrue Positive APositiveR2True Negative DFalse Negative CNegativeNC2C1Total预测值(predictive value)

第42页:灵敏度、特异度、患病率与预测值的关系

灵敏度、特异度、患病率与预测值的关系Relationship between sensitivity, specificity,prevalence and predict value

第43页:sensitivity

sensitivity and specificity in different blood sugar levelblood sugarSN SPblood sugarSN SP(mg/100ml)(﹪)(﹪)(mg/100ml)(﹪)(﹪)80 100.0 1.2 150 64.3 96.190 98.6 7.3 160 55.7 98.6100 97.1 25.3 170 52.9 99.6110 92.9 48.4 180 50.0 99.8120 88.6 68.2 190 44.3 99.8130 81.4 82.4 200 37.1 100.0140 74.3 91.2Relationship between sensitivity and specificity灵敏度与特异度的关系

第44页:非病人病人某项诊断标准的数值截断点

非病人病人某项诊断标准的数值截断点Threshold三、筛检试验截断值的确定Determination of screening cut-off point理想情况Ideal situation人数NumberNormalDisease

第45页:非病人,病人,某项诊断标准的数值,-,三

非病人Normal病人Abnormal某项诊断标准的数值Cut-off三、筛检试验截断值的确定Determination of screening cut-off point实际情况Actual situation人数Population

第46页:Number of persons

Number of personsMeasurementScreening tests use an arbitrary cut-off toseparate two populations(normal vs. abnormal)NormalAbnormalacbdNormalacdb

第47页:Number Measurement

NumberMeasurementWhere cut-off isplaceddeterminessensitivity andspecificityScreening tests use an arbitrary cut-off toseparate two populations(normal vs. abnormal)

第48页:Number Measurement

NumberMeasurementWhere cut-off isplaced determinessensitivity andspecificityNormalAbnormalFew False NegativesHigh Sensitivity-result+ resultScreening tests use an arbitrary cut-off toseparate two populations(normal vs. abnormal)

第49页:Number Measurement

NumberMeasurementWhere cut-off isplaced determinessensitivity andspecificityNormalAbnormalFew False PositivesHigh Specificity-result+ resultScreening tests use an arbitrary cut-off toseparate two populations(normal vs. abnormal)

第50页:Number Measurement

NumberMeasurementWhere cut-off isplaced determinessensitivity andspecificityNormalAbnormalTrade off betweenFalse–and False +-result+ resultScreening tests use an arbitrary cut-off toseparate two populations(normal vs. abnormal)

第51页:Number Measurement

NumberMeasurementTest with HighSensitivityNormalAbnormalA negative resultallows you to rule-outwhatever you aretesting-result+ resultSnNoutScreening tests use an arbitrary cut-off toseparate two populations(normal vs. abnormal)

第52页:Number Measurement

NumberMeasurementTest with HighSpecificityNormalAbnormalA positive result allowsyou to rule-in whateveryou are testing-result+ resultSpPinScreening tests use an arbitrary cut-off toseparate two populations(normal vs. abnormal)

第53页:用真阳性率和假阳性率作图得出的曲线

用真阳性率和假阳性率作图得出的曲线,可用于确定筛检试验的截断值。

A receiver operating characteristic (ROC),or simply ROCcurve, is a graphical is a graphical plot of the sensitivity,or true positives, vs. (1 − specificity), or false positives, fora binary classifier system as its discrimination threshold isvaried.受试者工作特性曲线Receiver operator characteristic curve, ROC

第54页:特异度血糖测定诊断糖尿病的ROC曲线截断

特异度血糖测定诊断糖尿病的ROC曲线截断点Cutoff pointROC curve for diagnosis of diabetes using blood glucose

第55页:第三节筛检效果评价

第三节筛检效果评价

  • 选择患病率高的人群
  • 选用高灵敏度的筛检试验
  • 采用联合试验
  • 串联
  • 并联Yield
  • To select the populationwith high prevalence rate
  • To select the test with highsensitivity
  • To design a combine test
  • Series test
  • Parallel test

第56页:二、筛检的生物学效果评价

二、筛检的生物学效果评价Biological effectiveness evaluation病死率、死亡率、生存率筛检组Screened group未筛检组Unscreened group比较Fatality rate、mortality rate、survival rate

第57页:三、筛检的卫生经济学效果评价

三、筛检的卫生经济学效果评价

  • 成本效果分析Cost-effectiveness analysis
  • 成本效益分析Cost-benefit analysis
  • 成本效用分析Cost-utility analysis

第58页:领先时间偏倚

领先时间偏倚

  • 病程长短偏倚
  • 志愿者偏倚Lead time biasLength biasVolunteer bias第四节筛检中的偏倚及其控制Bias and Control

第59页:领先时间偏倚

领先时间偏倚(lead time bias)领先时间:筛检诊断时间和临床诊断时间之差Leadtime:Intervalbetweenthediagnosisofadiseaseatscreeningandtheusualtimeofdiagnosis(bysymptoms)Diagnosisby screeningDiagnosisvia symptomsLead Time

第60页:Assumes survival

Assumes survival

  • Does not take into account lead time between diagnosis atscreening and usual diagnosis.Diagnosis byscreening in 1994Deathin 2008Survival = 14 years
  • 认为延长的生存时间是筛检诊断时间与死亡时间之差
  • 没有考虑筛检诊断时间和临床诊断时间之间的领先时间
  • 领先时间偏倚(lead time bias)

第61页:Diagnosis

Diagnosis

  • 领先时间偏倚(lead time bias)

第62页:病程长短偏倚

病程长短偏倚(length bias)疾病开始筛检查出症状开始死亡ODPYOBiologicalonset ofdiseaseYSymptomsBeginDDeathPDiseasedetectablevia screening

第63页:筛检、时间、恶性程度高、恶性程度低

  • 筛检ScreeningODPYODPYODPYODPYODPYOPYD时间Time恶性程度高Aggressive恶性程度低Less aggressive
  • 病程长短偏倚(length bias)

第64页:志愿者(、 、)

志愿者(volunteer bias)Type of bias where those who choose to participate arelikely to be different from those who don’t.筛检参加者与不参加者之间,某些特征可能存在不同而导致的偏倚。

第65页:致谢与结束页

谢谢!

顶部目录